Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BI 690517 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| BI 690517 mild hepatic impairment (Child-Pugh A) | EXPERIMENTAL | - |
| BI 690517 normal hepatic function | EXPERIMENTAL | control group |
| BI 690517 moderate hepatic impairment (Child-Pugh B) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BI 690517 | DRUG | BI 690517 |
Inclusion Criteria: * Male or female subjects aged at least 18 years at screening * Body mass index of 18.5 to 36.0 kg/m2 (inclusive) * Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial. * Women of childbearing potential1 and ...
BI 690517 is an investigational small molecule being studied for use in liver diseases. It is currently in Phase 1 clinical development, with a completed study evaluating how the drug is taken up in the body of people with and without liver problems.
BI 690517 is being developed by IQVIA Holdings, Inc., a company traded on the stock exchange under the ticker symbol IQV. The drug is in Phase 1 clinical development for liver diseases.
BI 690517 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials.
BI 690517 has one completed clinical trial, identified as NCT05731908, titled "A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems." This Phase 1 study enrolled 28 participants in the United States.
Yes, BI 690517 is being studied in healthy volunteers. The completed Phase 1 trial, NCT05731908, included healthy participants as well as those with liver problems, with a minimum age of 18 years.